Return to study ST001516 main page
MB Sample ID: SA127477
Local Sample ID: | PAG163_Inf |
Subject ID: | SU001590 |
Subject Type: | Human |
Subject Species: | Homo sapiens |
Taxonomy ID: | 9606 |
Age Or Age Range: | 2-12 years |
Weight Or Weight Range: | 11-30 Kilograms |
Height Or Height Range: | 85 - 137 cm |
Gender: | Male and female |
Human Ethnicity: | Gouin (Burkina Faso, West Africa) |
Human Inclusion Criteria: | residency in the Nafona- and Bounouna rural area in Burkina Faso, age of 2 to 12 years, no P. falciparum infection at the time of enrollment (as evidenced by malaria rapid diagnostic test and confirmed later with microscopy and qPCR), no fever (axillary temperature ≥37.5°C) or history of fever within the preceding 48 hours |
Human Exclusion Criteria: | history of immunosuppressive diseases or chronic diseases, signs of concomitant febrile illness or active infection, use of anti-malarial treatment within the preceding two weeks, use of immunosuppressant or other immune-modifying drugs within the preceding six months and receiving blood transfusion within the preceding three months |
Select appropriate tab below to view additional metadata details:
Subject:
Subject ID: | SU001590 |
Subject Type: | Human |
Subject Species: | Homo sapiens |
Taxonomy ID: | 9606 |
Age Or Age Range: | 2-12 years |
Weight Or Weight Range: | 11-30 Kilograms |
Height Or Height Range: | 85 - 137 cm |
Gender: | Male and female |
Human Ethnicity: | Gouin (Burkina Faso, West Africa) |
Human Inclusion Criteria: | residency in the Nafona- and Bounouna rural area in Burkina Faso, age of 2 to 12 years, no P. falciparum infection at the time of enrollment (as evidenced by malaria rapid diagnostic test and confirmed later with microscopy and qPCR), no fever (axillary temperature ≥37.5°C) or history of fever within the preceding 48 hours |
Human Exclusion Criteria: | history of immunosuppressive diseases or chronic diseases, signs of concomitant febrile illness or active infection, use of anti-malarial treatment within the preceding two weeks, use of immunosuppressant or other immune-modifying drugs within the preceding six months and receiving blood transfusion within the preceding three months |